With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

Manufacturing in Ireland has long helped many American drug companies pay lower taxes. But that strategy was designed for a ...

Finally, add PepsiCo (NASDAQ: PEP) to your list of S&P 500 dividend stocks to buy and hold forever while you can plug into ...

Potential for patient access and reimbursement/sale of Multikine in Saudi Arabia within approximately 60 days following ...

MSD's plan to reduce its headcount by around 6,000, first revealed a couple of weeks ago, looks like it will start at its ...

Exelixis’ EXEL year-to-date performance has been good. Shares of the biotech company have gained 15.6% compared with the ...

Phase 1b/2 in MSS CRC shows 19.4-month median OS (mOS) in 10 mg/kg dose cohorts; mOS for 20 mg/kg cohorts has not yet been reached Alignment with FDA on Phase 2 and Phase 3 trial design elements.

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

Strong performance driven by over 200% growth in product revenues year-on-year <li /> Best quarter in Alvotech's history in terms of op ...

The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.